U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002741

Chlorotrianisene (TACE®) is a powerful synthetic, non-steroidal estrogen used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. It may also be used to prevent breast engorgement following childbirth. Chlorotrianisene (TACE®) binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

Originator

Curator's Comment: Shelton, R.S. and Van Campen, M.G. Jr.; U S . Patent 2,430,891; November 18,1947; assigned to the Wm. S. Merrell Company.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TACE

Approved Use

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Curative
TACE

Approved Use

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Palliative
TACE

Approved Use

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Preventing
TACE

Approved Use

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Doses

Doses

DosePopulationAdverse events​
72 mg 2 times / day multiple, oral
Dose: 72 mg, 2 times / day
Route: oral
Route: multiple
Dose: 72 mg, 2 times / day
Sources:
healthy, 21 years
Health Status: healthy
Age Group: 21 years
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013-09-05
Treatments for suppression of lactation.
2009-01-21
An inventory of yeast proteins associated with nucleolar and ribosomal components.
2006
Tracing the origins of COX-2 inhibitors' structures.
2002-08
The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors.
1979-07-01
The choice of estrogen preparations in the treatment of prostatic cancer.
1975-11-08
Hydroxyurea in stage D carcinoma of the prostate: a pilot study.
1975-09
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Rat pituitary gland cells (2 x 10^5/dish) were cultured for 8 days with medium containing chlorotrianisene (TACE) or its demethylated derivative, 1,1,2-tri(4-hydroxyphenyl)chloroethylene (TCE), alone or with E2 (0.1 or 1 nM). TCE was a partial estrogen with antiestrogenic properties against E2 (0.1 nM). The antiestrogenic effect could also be reversed by increasing the concentration of E2 10-fold. TACE was less estrogenic and a less potent E2 antagonist.
Name Type Language
ADAM17
Preferred Name English
DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 17
Common Name English
TNF-ALPHA CONVERTASE
Common Name English
TNF-ALPHA-CONVERTING ENZYME
Common Name English
SNAKE VENOM-LIKE PROTEASE
Common Name English
TACE
Common Name English
Code System Code Type Description
UNIPROT
P78536
Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025
PRIMARY
DAILYMED
37OV8A66E1
Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025
PRIMARY
FDA UNII
37OV8A66E1
Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025
PRIMARY